Key result
Calcium antagonists may reduce reperfusion injury and expand the therapeutic window for thrombolysis.
Why the study?
Previous studies reported calcium antagonists reduce acute ischemic injury, but their effects on reperfusion-mediated myocardial damage mechanisms remain unclear.
Do calcium antagonists reduce myocardial ischemia reperfusion injury in experimental models?
Do calcium antagonists reduce myocardial ischemia reperfusion injury in experimental models?
Experimental evidence suggests calcium antagonists may reduce reperfusion injury through multiple mechanisms, potentially expanding the benefits of reperfusion therapy.
Calcium antagonists may mitigate experimental reperfusion injury; leaves open any clinical role pending prospective trials.
A number of previous studies have reported that administration of calcium antagonists reduces acute ischemic injury in a variety of experimental models. More recently, however, it has been suggested that the beneficial effects of reperfusing the ischemic myocardium might be blunted by the paradoxical occurrence of a specific form of reperfusion-mediated injury. Although the ultimate mechanisms responsible for this phenomenon have not been completely elucidated, it has been suggested that oxygen radical generation, neutrophil activation, and calcium overload, may all contribute to the development of myocardial damage in postischemic hearts. Several experimental studies suggest that, in addition to their well-known effects on ischemic injury, calcium antagonists may variably affect these mechanisms of reperfusion-mediated cell damage. In particular, evidence has been provided that suggests these drugs may inhibit oxygen radical-mediated peroxidation of membrane lipids and may also reduce activation of stimulated neutrophils. Furthermore, calcium-channel blockers might also prevent calcium overload in reperfused hearts, and they might interfere with reperfusion injury indirectly, secondary to a reduction in the severity of ischemia. From the experimental data available it can be speculated that calcium antagonists might contribute to reducing oxygen radical damage following reflow. At the same time, these drugs may allow the extension of the time window of reperfusion therapy, thus further expanding the benefits of thrombolysis.
No takes yet. Share an insight, caveat, or question.
Ambrosio et al. (1992) conducted a review in Myocardial Ischemia Reperfusion Injury. Calcium antagonists was evaluated. Experimental data suggest calcium antagonists may reduce oxygen radical damage following reflow and extend the time window of reperfusion therapy, expanding the benefits of thrombolysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: